Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob P Lalezari

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
AIDS (London, England)|March 17, 2023
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIVFelicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, et al.
The Journal of Infectious Diseases|April 9, 2026
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral LoadTanaya R Vaidya, Till Geib, Jacob P Lalezari, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Clinical Therapeutics|October 1, 2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19Harish Seethamraju, Otto O Yang, Richard Loftus, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvirKris V Kowdley, David R Nelson, Jacob P Lalezari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
AIDS (London, England)|March 17, 2023
Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIVFelicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, et al.
The Journal of Infectious Diseases|April 9, 2026
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral LoadTanaya R Vaidya, Till Geib, Jacob P Lalezari, et al.
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Clinical Therapeutics|October 1, 2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19Harish Seethamraju, Otto O Yang, Richard Loftus, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvirKris V Kowdley, David R Nelson, Jacob P Lalezari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
Nature Medicine|October 15, 2025
Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyMoti N Ramgopal, Jacob P Lalezari, Ana Gabriela Pires Dos Santos, et al.
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
The Journal of Infectious Diseases|April 10, 2010
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibodyJeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, et al.
Pageof 4